Lumito AB publishes Quarterly Report 1, 2025
First quarter 2025, January 1 to March 31 • Net sales amounted to TSEK 0 (17).• Result after taxes amounted to TSEK -11 803 (-7 113).• Earnings per share before and after dilution amounted to SEK -0,04 (-0,03).• Cash flow from operating activities after changes in working capital amounted to TSEK -6 784 (-7,178).• Cash […]
Lumito featured at AACR 2025
The AACR Annual Meeting (American Association for Cancer Research) is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. Lumito gained valuable visibility through a presentation by Professor Paul Waring at Akoya’s Spotlight Theatre, […]
Lumito and Concept Life Sciences join forces to advance tissue analysis in drug discovery
We are excited to announce a collaboration between Lumito and Concept Life Sciences, a CRO (contract research organisation) based in UK, to enhance tissue analysis in drug discovery and development. This joint project will focus on evaluating and optimising Lumito’s innovative product Scizys, within Concept Life Sciences’ cutting-edge research service. This collaboration is more than […]
Lumito AB publishes year-end report 2024
Financial Overview Fourth quarter 2024, October 1 to December 31• Net sales amounted to TSEK 79 (0).• Result after taxes amounted to TSEK-15,476 (-5,777).• Earnings per share before and after dilution amounted to SEK -0.06 (-0.03).• Cash flow from operating activities after changes in working capital amounted to TSEK -6,213 (-5,480). Full Year 2024, 1 […]
Lumito and Truly Labs join forces to drive innovation and enhanced competitiveness in tissue analysis
We are excited to announce that Lumito and Truly Labs are joining forces in a strategic partnership to develop innovative, value-driven solutions that provide both companies with a competitive edge in tissue analysis. “We are truly happy about this partnership where we will work together to improve the quality and objectivity of tissue analysis. Combining […]
The subscription price for exercise of warrants of series TO6 in Lumito AB is set to SEK 0.39 and the subscription period commences today November 4, 2024
Lumito AB (publ) ("Lumito" or the "Company") issued warrants of series TO6 in connection to an issue and loan financing during the fourth quarter of 2023. Each warrant gives the right to subscribe for one (1) new share in the Company. The subscription price for the warrants has been set to 70 percent of the […]
Lumito AB publishes Quarterly Report 3, 2024
Financial overview of the third quarter July 1 to September 30, 2024 Net sales amounted to TSEK 0 (0). Result after taxes amounted to TSEK -10 843 (-5 358). Earnings per share before and after dilution amounted to SEK -0,05 (-0,03). Cash flow from operating activities after changes in working capital amounted to TSEK -5 567 […]
Lumito signs Letter of Intent with Scientific Advisor
Lumito has signed a Letter of Intent with pathologist Paul Waring for strategic guidance regarding the market need for Lumito's products and future product development. Paul Waring is a highly experienced pathologist with approximately 35 years of leading and global experience in the hospital sector, academia, and industry. He initiated and drove the partnership between […]
Lumito AB signs a Letter of Intent with Katana Labs GmbH
Lumito has signed a "Letter of Intent” with Katana Labs in Germany to offer a cloud and AI-based image analysis solution to Lumito's future customers with "scanning-service agreements". For potential customers to easily evaluate Lumito's product SCIZYS, a "scanning service" is offered. This enables customers to evaluate the benefits of SCIZYS without first investing in […]
Lumito AB publishes Quarterly Report 2, 2024
First half of the year1 January – 30 June 2024 Net sales amounted to KSEK 17 (0). Result after taxes amounted to KSEK -15,244 (-14,668). Basic and diluted earnings per share amounted to SEK -0,06 (-0,07). Cash flow from operating activities after change in working capital amounted to KSEK -16,247 (-13,734). Cash and cash equivalents […]
